New compounds can kill many types of cancer

Molecule S63845 is capable of eliminating the source of cancer cells, slowing the process of developing the disease but does not cause side effects.

Scientists have just announced a new compound that inhibits the growth of many cancer cell samples in Nature magazine on October 19, according to Science Alert.

The molecule called S63845 works by blocking MCL1 protein, the protein that helps many types of cancer cells grow. Cancer cells will die without MCL1.

"MCL1 is an important protein for many types of cancer because it is a life-promoting protein that helps cancer cells avoid programmed cell death, which is a mechanism for the body to eliminate cells. Cancer , "Guillaume Lessene, from the Research Institute of Walter and Eliza Hall, Australia, a research team member, said.

The human immune system is difficult to destroy cancer cells because they grow and spread faster than the human body's protective mechanism can keep up.

Molecule S63845 can inhibit the development of many types of cancer. (Photo: Pete LinForth).

The use of chemotherapy or radiotherapy may be an effective way to remove cancer cells, but these techniques often kill both healthy cells and cause side effects of debilitating the body.

Therefore, molecule S63845 is a promising method because in addition to eliminating the source of cancer cell life, it can be used in doses that do not harm normal cells.

The finding could help researchers find ways to fight blood cancers like acute leukemia caused by bone marrow, lymphoma and multiple bone marrow tumors . It may also aid in the treatment of solid tumors , including melanoma and lung cancer or breast cancer.

"Extensive research on many cancer samples shows that the S63845 molecule attacks effectively on cancer cells that depend on MCL1 , " Lessene said.

The compound is the latest in a new line of anticancer drugs called BH3 minetics , aimed at proteins that cancer cells rely on to avoid and counteract programmed cell death.

"BH3 minetics inhibits a group of proteins called BCL-2 , which includes MCL1. Therefore, inhibiting MCL1 will activate the programmed cell death process , " Lessene explained. prefer.

This study is only in the clinical stage. The team will have to conduct many complex tests before developing it into a drug that patients can safely use.

"This finding opens up new hope for patients. We believe that the S63845 molecule is an accurate drug that can attack the nucleus of cancer cells and reduce its protective mechanisms. Studies and Future findings may help this compound fight many other cancers, "said Andrew Wei, hematology specialist, Alfred Hospital, Australia.